Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include emricasanum and VAY-785. Its PubChem CID is 12000240.
Emricasan
| CAS No | 254750-02-2 |
|---|---|
| Molecular Formula | C26H27F4N3O7 |
| Molecular Weight | 569.5 g/mol |
| Synonyms | (3S)-3-[[(2S)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
The listed CAS number is 254750-02-2.
The listed molecular formula is C26H27F4N3O7.
The listed molecular weight is 569.5 g/mol.
(3S)-3-[[(2S)-2-[[2-(2-tert-butylanilino)-2-oxoacetyl]amino]propanoyl]amino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid.
The source lists emricasanum and VAY-785.